JP5371969B2 - Ｐ２ｙ１２拮抗薬としてのピロール誘導体 - Google Patents

Ｐ２ｙ１２拮抗薬としてのピロール誘導体 Download PDF

Info

Publication number
JP5371969B2
JP5371969B2 JP2010512555A JP2010512555A JP5371969B2 JP 5371969 B2 JP5371969 B2 JP 5371969B2 JP 2010512555 A JP2010512555 A JP 2010512555A JP 2010512555 A JP2010512555 A JP 2010512555A JP 5371969 B2 JP5371969 B2 JP 5371969B2
Authority
JP
Japan
Prior art keywords
phenyl
methyl
pyrrol
piperazin
ethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010512555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530380A5 (https=
JP2010530380A (ja
Inventor
オトマー・クリングラー
イェルク・チェッヒ
ヴェルンガルト・チェヒティツキ
チーロ・ヴァイス
メリッタ・ユーシュト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2010530380A publication Critical patent/JP2010530380A/ja
Publication of JP2010530380A5 publication Critical patent/JP2010530380A5/ja
Application granted granted Critical
Publication of JP5371969B2 publication Critical patent/JP5371969B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
JP2010512555A 2007-06-18 2008-06-04 Ｐ２ｙ１２拮抗薬としてのピロール誘導体 Expired - Fee Related JP5371969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290755 2007-06-18
EP07290755.3 2007-06-18
PCT/EP2008/004459 WO2008155022A1 (en) 2007-06-18 2008-06-04 Pyrrole derivatives as p2y12 antagonists

Publications (3)

Publication Number Publication Date
JP2010530380A JP2010530380A (ja) 2010-09-09
JP2010530380A5 JP2010530380A5 (https=) 2011-07-07
JP5371969B2 true JP5371969B2 (ja) 2013-12-18

Family

ID=39092503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512555A Expired - Fee Related JP5371969B2 (ja) 2007-06-18 2008-06-04 Ｐ２ｙ１２拮抗薬としてのピロール誘導体

Country Status (12)

Country Link
US (1) US7910576B2 (https=)
EP (1) EP2167487B1 (https=)
JP (1) JP5371969B2 (https=)
KR (1) KR20100020478A (https=)
CN (1) CN101679358B (https=)
AU (1) AU2008266515B2 (https=)
BR (1) BRPI0812912A2 (https=)
CA (1) CA2690243A1 (https=)
IL (1) IL202758A (https=)
MX (1) MX2009013431A (https=)
MY (1) MY148901A (https=)
WO (1) WO2008155022A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051440A1 (en) 2006-10-20 2008-05-02 Novartis Ag Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-d ione
US9539246B2 (en) 2011-08-30 2017-01-10 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
MX2021012105A (es) 2019-04-03 2021-11-03 Aligos Therapeutics Inc Compuestos de pirrol.
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458515A (en) * 1966-07-21 1969-07-29 American Home Prod Piperazine substituted pyrroles
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US6956040B2 (en) * 2001-07-16 2005-10-18 Ranbaxy Laboratories Limited Oxazolidinone piperazinyl derivatives as potential antimicrobials
DE60333866D1 (de) 2002-12-11 2010-09-30 Bayer Schering Pharma Ag 2-aminocarbonlyl-chinolin-verbindungen als adenosin diphosphat plättchenrezeptor antagonisten
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US7273881B2 (en) * 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
CN1778801A (zh) * 2004-11-22 2006-05-31 中国农业科学院兰州畜牧与兽药研究所 喹诺酮7－((4－((z)－2－(2－氨基－4－噻唑基)－2－甲氧亚胺乙酰基)－1－哌嗪基)化合物及其制备方法
BRPI0606437A (pt) * 2005-01-06 2008-03-11 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
WO2006103544A2 (en) * 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
PT1951254E (pt) * 2005-11-03 2012-04-12 Portola Pharm Inc [4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas
US20070259879A1 (en) * 2006-03-06 2007-11-08 Trimeris, Inc. Piperazine and piperidine biaryl derivatives

Also Published As

Publication number Publication date
KR20100020478A (ko) 2010-02-22
HK1142593A1 (en) 2010-12-10
IL202758A0 (en) 2010-06-30
IL202758A (en) 2013-09-30
CA2690243A1 (en) 2008-12-24
WO2008155022A1 (en) 2008-12-24
EP2167487A1 (en) 2010-03-31
EP2167487B1 (en) 2015-02-18
CN101679358A (zh) 2010-03-24
MY148901A (en) 2013-06-14
JP2010530380A (ja) 2010-09-09
MX2009013431A (es) 2010-01-15
US20100226918A1 (en) 2010-09-09
AU2008266515B2 (en) 2014-05-01
US7910576B2 (en) 2011-03-22
AU2008266515A1 (en) 2008-12-24
CN101679358B (zh) 2013-10-30
BRPI0812912A2 (pt) 2014-12-09

Similar Documents

Publication Publication Date Title
JP5560202B2 (ja) Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
JP2011527677A (ja) Ｎｈｅ−１阻害剤として有用なピロリジニル及びピペリジニル化合物
EP3468956A1 (en) 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
JP2011507915A (ja) Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
CN104936944B (zh) 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
JP4939401B2 (ja) ＴＡＦＩａ阻害剤として用いるイミダゾール誘導体
JP2011511018A (ja) Ｐａｒ１阻害剤としてのｓｆ５誘導体、その製造、及び薬剤としての使用
JP5371969B2 (ja) Ｐ２ｙ１２拮抗薬としてのピロール誘導体
JP4608495B2 (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
US9776991B2 (en) Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
JP5422569B2 (ja) 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類
HK1142593B (en) Pyrrole derivatives as p2y12 antagonists
KR20060012636A (ko) 인자 Ｘａ 억제제로서의 아자인돌 유도체
KR101373533B1 (ko) 인자 Ｘａ 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체
KR20060136457A (ko) 인자 Ｘａ 억제제로서의 피롤-유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130917

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees